UK commission proposes staged approval and post-deployment oversight for medical AI
The UK National Commission published 44 recommendations on 10 September proposing staged MHRA authorization and post-deployment surveillance for medical AI, including recording device versions in patient records.
On 10 September, the UK's National Commission on the Regulation of AI in Healthcare published 44 recommendations. One of the most concrete: record the identifier and version of an AI-based medical device in the patient's medical record. The goal is to give clinical sites a retrospective audit tool, so they can audit outcomes for patients whose care involved a specific system version.
The document is addressed to the MHRA (Medicines and Healthcare products Regulatory Agency), the government, and healthcare organizations. These are recommendations for a future regulatory framework.
Recommendation 14 sets out a staged pathway. MHRA would initially authorize a device only under specified conditions of use, following a review of baseline data, risk controls, and reporting requirements. Expanding the scope of use becomes possible only after the system meets predefined safety and performance thresholds. Patients are informed that the authorization is provisional, and the conditions for full authorization are described upfront.
Medical AI can change after updates and perform differently across clinical settings, depending on local data and workflows. The current UK system for assessing medical devices places greater weight on pre-market evidence, and post-market surveillance relies largely on incident reports. The commission proposes collecting evidence and maintaining oversight throughout the system's entire lifecycle: mandatory surveillance plans, real-world performance studies, and periodic reporting on how devices perform. If performance deteriorates, a predefined escalation procedure should apply.
Responsibility is divided between the manufacturer and the clinical site. Manufacturers describe the conditions for safe use in advance, including staff training and the site's organizational readiness to work with the system. A contract between the two allocates obligations on each side. The site is also responsible for training its own staff to work with the specific technology.
If these recommendations shape future regulation, clinical AI developers will face additional obligations: post-market real-world performance studies, periodic reporting on system behavior, and contractual allocation of responsibility with clinical sites. Len Post's investor profile is available in the Eternal Search database at the link below.
Open the related Eternal Search page
Sources
[1] gov.uk
The 10 September MHRA recommendations were selected because they introduce a concrete, lifecycle-wide accountability model for medical AI with specific mechanisms: staged conditional approval, post-deployment performance surveillance, and device-version recording in patient records. This is a substantive policy direction with direct cost and liability implications for clinical AI developers and their investors. The Len Post page is an investor profile in the Eternal Search database. The editorial step required by the approved concept (confirming his specific connection to a medical AI developer) could not be completed: the source material does not establish that connection, and the live Eternal Search page was inaccessible for verification in this session. The post therefore covers the regulatory framework in full and links his profile honestly as a resource for readers tracking investment in this space, without asserting any portfolio claim.